[Pharmacokinetics of BMY-28100 in multiple administration].
A multiple dose trial of BMY-28100, a new oral cephalosporin, was performed in volunteers, in order to evaluate its safety and pharmacokinetics. BMY-28100 was administered orally 250 mg t.i.d. for 7 days to seven healthy adult males. No side effects nor abnormal laboratory findings were observed. Peak levels of serum concentration and half-lives after the first and 19th administrations were 4.45 and 4.83 micrograms/ml and 1.3 and 1.1 hours, respectively. Urinary recoveries in 24 hours were 53.4% on day 1 and 56.2% on day 7. There was no tendency towards accumulation in blood upon continuous daily dosing of 250 mg t.i.d.
Motohiro
T
T
Department of Pediatrics, School of Medicine, Kurume University.
Kawakami
A
A
Sasaki
H
H
Aramaki
M
M
Sakata
Y
Y
Tominaga
K
K
Yamashita
F
F
Nakanomyo
H
H
Hiraoka
M
M
Ishikawa
K
K
D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D012016:Reference Values; D000097670:Cefprozil
D002214:Capsules; D002511:Cephalosporins; D000097670:Cefprozil